Aleniglipron - Gasherbrum Bio
Alternative Names: GSBR-1290Latest Information Update: 20 May 2025
At a glance
- Originator Gasherbrum Bio
- Developer Gasherbrum Bio; Structure Therapeutics
- Class Antihyperglycaemics; Antiparkinsonians; Obesity therapies; Small molecules
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity; Type 2 diabetes mellitus
- Preclinical Parkinson's disease
Most Recent Events
- 08 May 2025 Preclinical trials in Parkinson's disease in USA (PO) before May 2025
- 08 May 2025 Structure Therapeutics completes enrolment in the IIb ACCESS trial for Obesity in USA (NCT06693843)
- 08 May 2025 Structure Therapeutics completes enrolment in the phase II ACCESS II trial in Obesity in USA (NCT06703021)